Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma

Acta Oncologica

Volumn 41, Issue 1, 2002, Pages 91-97

  Li, Lingyun ^a   Rojiani, Amyn M ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CHEMOTHERAPY; PATIENT MONITORING; RADIATION;

ANTITUMOR EFFICACY;

SODIUM COMPOUNDS;

CISPLATIN; COMBRETASTATIN A4; VINBLASTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; KAPOSI SARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; CISPLATIN; DRUG EVALUATION, PRECLINICAL; MICE; MICE, NUDE; SARCOMA, EXPERIMENTAL; SARCOMA, KAPOSI; STILBENES; TIME FACTORS; TUMOR STEM CELL ASSAY; VINBLASTINE; WHOLE-BODY IRRADIATION;

EID: 0036215178     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602317314127     Document Type: Article

References (26)

1. Biology and therapy of epidemic Kaposi's sarcoma
2. Kaposi's sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy
3. Kaposi's sarcoma: Advances in tumor biology and pharmacotherapy
4. Noncytotoxic approaches to the treatment of HIV-associated Kaposi's sarcoma
5. Systemic treatment of Kaposi's sarcoma: Current status and future directions
6. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma
7. AIDS-associated Kaposi's sarcoma
8. Kaposi's sarcoma. New treatment modalities
9. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS clinical trial group study
10. Activity of thalidomide in AIDS-related Kaposi's sarcoma
11. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre
12. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of Aids-associated Kaposi's sarcoma
13. Isolation and characterization of an immortal neoplastic cell line (KSY-1) from AIDS-associated Kaposi's sarcoma
14. Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes
15. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872
16. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
17. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma
18. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches
19. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
20. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel
21. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
22. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
23. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents
24. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
25. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
26. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors